Carfilzomib (PR-171)

by
Updated: Dec 9, 2009
Brand Name:
Generic Name: carfilzomib
Code Name: PR-171
Company: Onyx Pharmaceuticals
FDA Clinical Phase: 1, 2, & 3

Description:
Carfilzomib (news articles), which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that carfilzomib has an encouraging safety profile, with low levels of neuropathy (a common side effect for many myeloma treatments). A Phase 2 trial with relapsed and refractory myeloma patients has recently closed enrollment, and results are expected in late 2010.

Clinical Trials:
For a list of clinical trials studying carfilzomib for the treatment of multiple myeloma, see ClinicalTrials.gov.

Official Web site for Carfilzomib: http://www.onyx-pharm.com/view.cfm/632/Carfilzomib

Tags:

Related Articles:

Leave a comment

Comments and feedback are welcomed. If you would like to leave a comment, please fill out the form below. You can also subscribe to comments for this article via RSS.